AU2017346516B2 - Piperidine derivatives as inhibitors of ubiquitin specific protease 7 - Google Patents

Piperidine derivatives as inhibitors of ubiquitin specific protease 7 Download PDF

Info

Publication number
AU2017346516B2
AU2017346516B2 AU2017346516A AU2017346516A AU2017346516B2 AU 2017346516 B2 AU2017346516 B2 AU 2017346516B2 AU 2017346516 A AU2017346516 A AU 2017346516A AU 2017346516 A AU2017346516 A AU 2017346516A AU 2017346516 B2 AU2017346516 B2 AU 2017346516B2
Authority
AU
Australia
Prior art keywords
methyl
pyrimidin
piperidin
hydroxy
phenylbutanoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
AU2017346516A
Other languages
English (en)
Other versions
AU2017346516A1 (en
Inventor
Fabio BROCCATELLI
Frank Burkamp
James John CRAWFORD
Lewis Gazzard
Tim Harrison
Matthew HELM
Peter Hewitt
Miel HUGUES
Linda Jordan
Wendy Lee
Colin O'dowd
Shane ROUNTREE
Ingrid WERTZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of AU2017346516A1 publication Critical patent/AU2017346516A1/en
Application granted granted Critical
Publication of AU2017346516B2 publication Critical patent/AU2017346516B2/en
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
AU2017346516A 2016-10-20 2017-10-20 Piperidine derivatives as inhibitors of ubiquitin specific protease 7 Revoked AU2017346516B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1617758.6A GB201617758D0 (en) 2016-10-20 2016-10-20 Pharmaceutical compounds
GB1617758.6 2016-10-20
PCT/GB2017/053175 WO2018073602A1 (en) 2016-10-20 2017-10-20 Piperidine derivatives as inhibitors of ubiquitin specific protease 7

Publications (2)

Publication Number Publication Date
AU2017346516A1 AU2017346516A1 (en) 2019-05-02
AU2017346516B2 true AU2017346516B2 (en) 2021-10-14

Family

ID=57738053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017346516A Revoked AU2017346516B2 (en) 2016-10-20 2017-10-20 Piperidine derivatives as inhibitors of ubiquitin specific protease 7

Country Status (16)

Country Link
US (1) US10766903B2 (enExample)
EP (2) EP3529241B1 (enExample)
JP (2) JP7073359B2 (enExample)
KR (1) KR20190069529A (enExample)
CN (1) CN110088096A (enExample)
AU (1) AU2017346516B2 (enExample)
BR (1) BR112019007977A2 (enExample)
CA (1) CA3040805A1 (enExample)
DK (1) DK3529241T3 (enExample)
ES (1) ES2914284T3 (enExample)
GB (1) GB201617758D0 (enExample)
IL (1) IL266146A (enExample)
MX (2) MX2019004450A (enExample)
RU (1) RU2019115115A (enExample)
SG (1) SG11201903456WA (enExample)
WO (1) WO2018073602A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612938D0 (en) 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
EP3687537A4 (en) * 2017-09-26 2021-06-16 Dana-Farber Cancer Institute, Inc. Novel usp7 inhibitors for treating multiple myeloma
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
UY38423A (es) * 2018-10-19 2021-02-26 Servier Lab Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
EP3870179A4 (en) * 2018-10-22 2022-11-23 Dana Farber Cancer Institute, Inc. Usp7 inhibition
CN109912598B (zh) * 2019-03-27 2022-09-13 四川大学华西医院 防治炎症反应的核苷类衍生物及其应用
CN117050086A (zh) * 2019-04-11 2023-11-14 四川科伦博泰生物医药股份有限公司 含有并环基团的嘧啶酮并吡唑类化合物、其制备方法及用途
WO2020207352A1 (zh) * 2019-04-11 2020-10-15 四川科伦博泰生物医药股份有限公司 三嗪酮并咪唑类化合物及其医药用途
WO2020227365A1 (en) * 2019-05-06 2020-11-12 Integral Early Discovery, Inc. Inhibiting usp19
CN118108744A (zh) * 2020-01-08 2024-05-31 四川科伦博泰生物医药股份有限公司 异噻唑并嘧啶酮类化合物，包含其的药物组合物及其用途
CN112608320B (zh) * 2020-01-16 2023-03-17 中国药科大学 哌啶类化合物及其制备方法和医药用途
GB202001980D0 (en) * 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
CN115427076B (zh) 2020-02-28 2025-01-03 免疫学有限公司 用于治疗冠状病毒感染的人去泛素化酶抑制剂
CN113801135B (zh) * 2020-06-15 2025-06-24 四川科伦博泰生物医药股份有限公司 噻吩并吡唑类化合物，包含其的药物组合物及其用途
CN112047933B (zh) * 2020-10-15 2022-06-14 郑州大学 喹唑啉酮类usp7抑制剂及其制备方法和应用
CN114478437A (zh) * 2020-11-11 2022-05-13 山东特珐曼药业有限公司 一种制备n-甲基-2-吡咯烷乙胺或其盐的方法
CN113336714A (zh) * 2021-06-25 2021-09-03 山东大学 一种化合物及其制备方法和应用
US20240358842A1 (en) * 2021-06-25 2024-10-31 Stablix, Inc. Protein stabilizing compounds containing usp7 ligands
US20240376076A1 (en) * 2021-07-20 2024-11-14 Dana-Farber Cancer Institute, Inc. Inhibitors targeting ubiquitin specific protease 7 (usp7)
GB202200753D0 (en) 2022-01-21 2022-03-09 Almac Discovery Ltd Pharmaceutical compounds
CN114507278B (zh) * 2022-01-27 2023-04-25 苏州大学 一种犹素探针UFM1-Lys-TAMRA及其合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030218A1 (en) * 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7
US20160185785A1 (en) * 2014-12-30 2016-06-30 Forma Therapeutics, Inc. Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
US20160229864A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US20160229833A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
WO2018020242A1 (en) * 2016-07-26 2018-02-01 Almac Discovery Limited Pharmaceutical compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO111096A0 (en) 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
ZA986594B (en) 1997-07-25 1999-01-27 Abbott Lab Urokinase inhibitors
WO2004058763A1 (en) 2002-12-23 2004-07-15 Merck & Co., Inc. 4(spiropiperidinyl)methyl substituted pyrrolidines as modulators of chemokine receptor activity
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
JP4787529B2 (ja) 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
US7884207B2 (en) 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
AU2006272876A1 (en) 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
EP1749822B1 (en) 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
JP2009526747A (ja) 2006-02-16 2009-07-23 武田薬品工業株式会社 環状アミン化合物および高血圧の予防・治療のための用途
JP5406722B2 (ja) 2006-10-16 2014-02-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体
US7875613B2 (en) 2006-10-30 2011-01-25 Hybrigenics Sa Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
MX2010006108A (es) 2007-12-11 2010-06-25 Hoffmann La Roche Inhibidores de estearoil-coa-desaturasa.
WO2009104802A1 (en) 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
KR20110036044A (ko) 2008-07-18 2011-04-06 다케다 파머수티컬 컴패니 리미티드 벤즈아제핀 유도체들 및 히스타민 ｈ3 길항제로서 이들의 용도
MX2011001259A (es) 2008-08-01 2011-03-15 Biocryst Pharm Inc Derivados de piperidina como inhibidores jak3.
CA2771226A1 (en) 2008-08-22 2010-02-25 James Madden New bradykinin b1 antagonists
EP2208725A1 (en) 2009-01-13 2010-07-21 Hybrigenics S.A. Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications
US8680139B2 (en) 2009-04-01 2014-03-25 Progenra Anti-neoplastic compounds, compositions and methods
EP2515657A4 (en) 2009-12-21 2013-07-03 Merck Sharp & Dohme Tyrosine kinase inhibitor
EP2357176A1 (en) 2010-01-15 2011-08-17 Hybrigenics S.A. Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7
TWI503323B (zh) 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
CN103025725B (zh) 2010-08-10 2015-09-16 安斯泰来制药有限公司 杂环化合物
JP2012072067A (ja) 2010-09-28 2012-04-12 Astellas Pharma Inc 含窒素芳香族へテロ環化合物
GB201114448D0 (en) 2011-08-22 2011-10-05 Takeda Pharmaceutical Compounds and their use
JP6117191B2 (ja) * 2011-10-07 2017-04-19 武田薬品工業株式会社 神経変性疾患の治療に有用な１−アリールカルボニル−４−オキシ−ピペリジン化合物
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
SG11201600241RA (en) 2013-07-18 2016-02-26 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
PL3227297T3 (pl) 2014-12-05 2021-10-25 Array Biopharma, Inc. 4,6 podstawione-pyrazolo[1,5-a]pirazyny jako inhibitory kinaz janusowych
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
CN107531683B (zh) 2015-03-20 2022-05-13 豪夫迈·罗氏有限公司 Usp7抑制剂化合物及使用方法
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US11136409B2 (en) * 2016-09-20 2021-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030218A1 (en) * 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7
US20160185785A1 (en) * 2014-12-30 2016-06-30 Forma Therapeutics, Inc. Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
US20160229864A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US20160229833A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
WO2018020242A1 (en) * 2016-07-26 2018-02-01 Almac Discovery Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
MX2021012589A (es) 2021-11-12
ES2914284T3 (es) 2022-06-08
BR112019007977A2 (pt) 2019-07-09
US20190256518A1 (en) 2019-08-22
RU2019115115A3 (enExample) 2020-11-24
CN110088096A (zh) 2019-08-02
WO2018073602A1 (en) 2018-04-26
EP3529241A1 (en) 2019-08-28
JP7073359B2 (ja) 2022-05-23
SG11201903456WA (en) 2019-05-30
JP2022106953A (ja) 2022-07-20
GB201617758D0 (en) 2016-12-07
JP2019535664A (ja) 2019-12-12
EP4026832A1 (en) 2022-07-13
IL266146A (en) 2019-06-30
MX2019004450A (es) 2019-08-05
KR20190069529A (ko) 2019-06-19
US10766903B2 (en) 2020-09-08
EP3529241B1 (en) 2022-04-06
DK3529241T3 (da) 2022-07-11
AU2017346516A1 (en) 2019-05-02
CA3040805A1 (en) 2018-04-26
RU2019115115A (ru) 2020-11-24

Similar Documents

Publication Publication Date Title
AU2017346516B2 (en) Piperidine derivatives as inhibitors of ubiquitin specific protease 7
AU2020274083B9 (en) FGFR inhibitors and methods of use thereof
AU2014369457B2 (en) Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors
TW202246255A (zh) Ｃｄｋ抑制劑及其使用方法
KR20140071361A (ko) 피라졸로[3,4-c]피리딘 화합물 및 사용 방법
EP3746432B1 (en) 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19)
US20250115598A1 (en) Bifunctional arylsulphonamide compounds
CA3121376A1 (en) Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)

Legal Events

Date Code Title Description
MAK Offer to surrender letters patent
MAL Surrender and revocation of letters patent

Effective date: 20221222